photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer

FOLFIRINOX Induces a Full Pathological Response Leading to Resectability in Pancreatic Cancer

The four-drug FOLFIRINOX regimen represents a standard-of-care initial treatment for pancreatic cancer (ductal adenocarcinoma of the pancreas) despite substantive side-effects. Along with the gemcitabine plus Abraxane combination therapy it appears to offer survival advantage in pancreatic cancer over gemcitabine given alone. And increasingly, FOLFIRINOX is offered as therapy for locally advanced and “borderline resectable” pancreatic […]

Saliva, Exosomes and MicroRNA for Pancreatic Cancer Detection – what’s not to like !

Dental research for pancreatic cancer has seemed to fall largely into two categories: specific bacterial overgrowth that may be associated in some manner with increased pancreatic cancer (ductal adenocarcinoma of the pancreas), and that related to exosomes, the free-floating “bubbles” found in saliva that we now know contains genetic materials (DNA and RNA) including mutations […]

Better Outcomes in Pancreatic Cancer with Select Treatments for Select Genetic Mutations ?

Some pancreatic cancer patients (hereinafter referring just to those with ductal adenocarcinoma of the pancreas) have substantially better outcomes than the majority. In the paper now reviewed by this blog entry (link at the end of this article) as published in the October 2016 issue of Endocrine-related Cancer journal, the French authors summarize surveillance, prognosis […]

Page 3 of 3712345...102030...Last »
Facebook
Facebook